1. Home
  2. PCVX vs KNX Comparison

PCVX vs KNX Comparison

Compare PCVX & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • KNX
  • Stock Information
  • Founded
  • PCVX 2013
  • KNX 1989
  • Country
  • PCVX United States
  • KNX United States
  • Employees
  • PCVX N/A
  • KNX N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • KNX Trucking Freight/Courier Services
  • Sector
  • PCVX Health Care
  • KNX Industrials
  • Exchange
  • PCVX Nasdaq
  • KNX Nasdaq
  • Market Cap
  • PCVX 4.4B
  • KNX 7.2B
  • IPO Year
  • PCVX 2020
  • KNX 1994
  • Fundamental
  • Price
  • PCVX $36.14
  • KNX $46.92
  • Analyst Decision
  • PCVX Strong Buy
  • KNX Buy
  • Analyst Count
  • PCVX 10
  • KNX 16
  • Target Price
  • PCVX $136.50
  • KNX $53.88
  • AVG Volume (30 Days)
  • PCVX 1.5M
  • KNX 2.7M
  • Earning Date
  • PCVX 08-05-2025
  • KNX 07-23-2025
  • Dividend Yield
  • PCVX N/A
  • KNX 1.52%
  • EPS Growth
  • PCVX N/A
  • KNX 37.21
  • EPS
  • PCVX N/A
  • KNX 0.93
  • Revenue
  • PCVX N/A
  • KNX $7,411,973,000.00
  • Revenue This Year
  • PCVX N/A
  • KNX $2.97
  • Revenue Next Year
  • PCVX N/A
  • KNX $6.76
  • P/E Ratio
  • PCVX N/A
  • KNX $50.72
  • Revenue Growth
  • PCVX N/A
  • KNX 1.16
  • 52 Week Low
  • PCVX $27.66
  • KNX $36.69
  • 52 Week High
  • PCVX $121.06
  • KNX $61.51
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 57.77
  • KNX 58.84
  • Support Level
  • PCVX $31.79
  • KNX $46.91
  • Resistance Level
  • PCVX $36.89
  • KNX $49.23
  • Average True Range (ATR)
  • PCVX 1.51
  • KNX 1.32
  • MACD
  • PCVX 0.37
  • KNX 0.22
  • Stochastic Oscillator
  • PCVX 77.65
  • KNX 62.46

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: